Media Contacts

For more information contact our media team:

Stacy Sevcik
+1 314 529 3062
Send Email >

Next Event

  • e-Health Research International Congress 2016

    Paris, France
    Oct11 – 12, 2016

    Learn More

Kantar Health thought leaders are available to comment on a variety of healthcare- and pharma-industry-related topics. In addition, our proprietary data is available for media use, including patient population sizes, treatment rates and patient-reported behaviors and attitudes.

Welcome to the Kantar Health News Room RSS Feed News

Delivering the most current and unique insights on healthcare trends and news about Kantar Health.

Kantar Health to Present Recent Oncology Clinical Developments

Jul 1, 2014

NEW YORK, June 30, 2014—Kantar Health, a leading global healthcare consulting firm, today announced it will host its 10th annual seminar in Tokyo highlighting the implications of recent drug approvals and clinical results in the oncology competitive landscape for pharmaceutical companies. The seminar is presented in conjunction with Synix Inc., Kantar Health’s partner in Japan.

The seminar will take place at Conference Square M+ in Tokyo on Thursday, July 10, and will be led by Tatiana Spicakova, Ph.D., Consultant, Clinical and Scientific Assessment, and Richard Wagner, Ph.D., Vice President, Oncology Commercial Strategies. The session will cover the drug development and treatment trends reported during recent oncology conferences.

  • Gastrointestinal Cancers (Colorectal and Gastric)
    • Discussion of recent developments to determine best choice of therapy in first-line colorectal cancer (CALGB 80405) and in relapsed/refractory colorectal and gastric cancers (Cyramza (ramucirumab, Eli Lilly), Lonsurf (TAS-102, Taiho))
  • Breast Cancer
    • Discussion of recent data and market impact associated with development in hormone receptor-positive breast cancer, as well as ongoing advances in triple-negative disease
  • Prostate Cancer
    • A review of the current treatment landscape and new early-phase data that could have an impact on this market in the future
  • Melanoma
    • A review of pivotal new data for BRAF inhibitors and PD-1/PD-L1 inhibitors and a discussion of the future evolution of treatment in this disease
  • Non-Small Cell Lung Cancer
    • A discussion of recent developments in relapsed/refractory disease (Cyramza (necitumumab, Eli Lilly), pembrolizumab (Merck)) and next-generation inhibitors in biomarker subpopulations (EGFR, ALK)
  • Immunotherapy
    • Discussion of new data for PD-1/PD-L1 inhibitors and other immunotherapeutics in development, with a review of development strategies
  • Chronic Lymphocytic Leukemia
    • Discussion of recent pivotal data (Imbruvica (ibrutinib, Pharmacyclics/Janssen), idelalisib (Gilead), Arzerra (ofatumumab, GSK/Genmab), Gazyva (obinutuzumab, Genentech/Roche)) and the rapidly changing standard of care in this disease
  • Novel Mechanisms of Action
    • A brief highlight of some of the upcoming mechanisms of action in development that could have a large clinical impact, including inhibitors of CDK, PARP, stem cell pathway and novel combination strategies

To register for this seminar, please visit or contact Hiroe Kujirai at

About Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.


Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit